66
Participants
Start Date
December 31, 2006
Primary Completion Date
February 28, 2011
Study Completion Date
January 31, 2012
EMD 521873
"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
EMD 521873
"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
EMD 521873
"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
Universitäts-Klinikum Mainz III.Medizinische Klinik, Mainz
Medizinische Klinik Universitätsklinikum Mannheim Medizinische Fakultät Mannheim, Mannheim
Istituto Oncologico della Svizzera Italiana Ospedale Regionale Bellinzona e Valli (IOSI), Bellinzona
University of Lausanne Hospitals (CHUV) and Hospitals of Riveria-Chablais, Lausanne
Kantonsspital St. Gallen, Sankt Gallen
Merck KGaA, Darmstadt, Germany
INDUSTRY